Summary The GER human pancreatic carcinoma cell line possesses receptors for 1,25-dihydroxyvitamin D3. We report that the vitamin D analogue EB 1089 inhibits the growth of these cells in vitro and when grown as tumour xenografts in immunodeficient mice. Tumour-bearing mice were given EB 1089 at a dose of 5 gg kg-' body weight i.p. thrice weekly for 4-6 weeks. Tumour growth was significantly inhibited in treated animals compared with controls in the absence of hypercalcaemia. These findings may have therapeutic implications in pancreatic cancer.
cancer but no effective chemotherapy has been developed for patients with advanced disease. Initially, the presence of oestrogen receptors (ER) in this tumour suggested that it might be responsive to endocrine therapy (Andren-Sandberg and Backman, 1990; Poston et al, 1990) , but clinical trials with the anti-oestrogen tamoxifen have not proved to be encouraging (Bakkevold et al, 1990; Taylor et al, 1993; Wong and Chan, 1993) .
Receptors for another steroid hormone, 1,25-dihydroxyvitamin D3 [1, 25(OH) 2D3, the active form of vitamin D3] are also present in GER, an extensively characterized cell line derived from a primary human pancreatic adenocarcinoma that has been shown to produce xenografts in nude mice (Grant et al, 1979 (Grant et al, , 1992 (Grant et al, , 1993 . 1,25-(OH)2D3 is known to inhibit the proliferation in vitro of a number of established cancer cell lines (Colston et al, 1981; Frampton et al, 1983; Dokoh et al, 1984) , but its potent calcium-mobilizing activity in vivo limits its potential as a therapeutic agent in hyperproliferative disorders. Recently, new synthetic analogues of vitamin D have been developed that have been shown to exhibit potent anti-tumour effects in animal models of breast cancer without causing marked hypercalcaemia (Abe et al, 1991; Colston et al, 1992a and b) . These analogues are currently under evaluation in phase MI/I trials in patients with breast cancer. In this preliminary report, we have extended our study of these compounds to pancreatic carcinoma and have assessed the effects of the synthetic vitamin D analogue EB 1089 on both the progression of xenografts developed from GER pancreatic adenocarcinoma cells and the growth of cultured pancreatic adenocarcinoma cells in vitro. Our results demonstrate that this novel vitamin D analogue exhibits significant anti-tumour activity both in vitro and in vivo, suggesting it should be considered as a potential candidate for therapy in pancreatic carcinoma. (Grant et al, 1979) were seeded into 24-well plates (2 x 104 cells per well) and were cultured in RPMI 1640 medium supplemented with 2.5% fetal calf serum, 2 mm glutamine, 100 U penicillin ml-' and 100 jg streptomycin ml-' at 37°C in a humidified atmosphere of 5% carbon dioxide for 24 h before treatment. EB 1089 or 9-cis retinoic acid was added in ethanol (0.1% final media concentration) to give final concentrations of 0.1-100 nm. Controls received ethanol alone and medium was changed every second day. Cell number was assessed by crystal violet assay (Wosikowski et al, 1993) . MCF-7 breast and MIA PaCa-2 pancreatic cancer cells were routinely maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 5% fetal calf serum.
Western analysis and ligand binding ER and vitamin D receptor (VDR) and p53 expression in cell cultures were determined by Western analysis. MCF-7 breast and GER pancreatic carcinoma cells were treated over a period of 1-4 days with EB 1089 (10 nM). After treatment, cell lysates were prepared as previously described (James et al, 1994) . Equivalent protein extracts (5-15 gg) were electrophoresed on 10% SDS poly- Animal protocol Female nude (Nu/Nu, MFI strain) mice, 6-8 weeks of age (Olac, UK) were maintained on sterilized tap water and irradiated standard rodent chow. GER pancreatic tumour xenografts were developed as previously described (Grant et al, 1979) , and mice bearing palpable tumours (0.2-0.4 cm in diameter) were randomly assigned to treated or control (vehicle-alone) groups. EB 1089 was given intraperitoneally in 0.1 ml of propylene glycol/0.05 M disodium hydrogen phosphate (4:1, v/v). Tumour volume was determined weekly as previously described (Colston et al, 1992a) . No tumour exceeded 1.2 cm in diameter or 10% of total body weight. At the end of each experiment animals were exsanguinated under halothane anaesthesia and serum was stored at -20°C until analysed.
Statistical methods
Percentage change in total tumour volume at each week of study was compared between groups using the non-parametric Mann-Whitney U-test. Comparisons of the biochemical and in vitro studies used the unpaired Student's t-test.
RESULTS
Ligand binding assays with cytosols from GER pancreatic carcinoma cells showed that the cells were VDR positive (63 fmol mg-' cytosol protein) but these cells did not contain detectable amounts of ER ( Figure IA) . A similar pattern of receptor expression was seen with MIA PaCa-2 cells (VDR 24 and ER < 1 fmol mg-' cytosol protein). ER protein could not be detected by Western analysis in GER cells but was readily detected in MCF-7 breast cancer cells ( Figure 1B ). VDR protein was detected by Western blot analysis in both GER and MCF-7 cell lines and treatment of these cells with 10 nM EB 1089 for 4 days increased the level of VDR protein ( Figure IC) . In MCF-7 cells, EB 1089 increased p53 protein levels at 4 days. Treatment of GER cells with EB 1089 for 24, 48 and 96 h revealed no appreciable difference in p53 protein levels relative to controls ( Figure IC) . Cell proliferation studies showed that the analogue EB 1089 produced a dose-dependent inhibition of the growth of GER cells. Maximal effects were seen at a concentration of 100 nm ( Figure  2A ). Inhibition of growth was also observed over a period of 8 days with the vitamin D analogue and also with the same concentration (100 nM) of 9-cis retinoic acid ( Figure 2B ).
The effects of EB 1089 on in vivo pancreatic carcinoma growth were evaluated using GER tumour xenografts. Dose regimens were chosen on the basis of our previous findings in rats, which have indicated that the elimination half-life of EB 1089 is in the order of 3-5 h (Binderup et al, 1991) . Initially, the analogue was given intraperitoneally to mice bearing tumour xenografts at doses of 2.5 and 5 gg kg-' body weight three times a week for 4 weeks.
At a dose of 5 ,ug kg-' thrice weekly, EB 1089 caused significant inhibition of growth ( Figure 3A) . Mean serum calcium in controls was 2.19 ± 0.053 mmol 1-' and 2.49 ± 0.074 mmol 1-' in the treated group (P < 0.01). There was no significant difference in body weight between control and treated groups at 4 weeks and treated animals remained healthy. However, animals treated with 5 jig kg-' five times weekly showed weight loss after 2 weeks of treatment (mean serum calcium in animals treated with this dose regimen was 2.81 ± 0.068 mmol 1-'). At this time, mean tumour volume was 85% of initial value. With the lower dose (2.5 jig kg-' thrice weekly), differences between treated and control groups were not significant at 28 days (P = 0.24). Finally, effects of EB 1089 (5 jg kg-' thrice weekly) were compared with those of 5-fluorouracil (20 mg kg-'). Figure 3B illustrates the tumour growth curves with these two agents. At the end of the 6 week treatment period, significant inhibition of tumour progression was observed in the group receiving EB 1089 (P = 0.007). However, differences between 5-fluorouracil-treated and control groups were not significant (P = 0.068 Mann-Whitney U-test).
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DISCUSSION
Our studies demonstrate that pancreatic adenocarcinoma cells possess specific receptors for 1,25(OH)2D3 (VDR) and are functionally responsive to the growth inhibitory effects of the vitamin D analogue EB 1089 both in vitro and in vivo. As far as we are aware, this is the first demonstration that a vitamin D derivative may demonstrate in vivo anti-tumour effects in a xenograft model of pancreatic adenocarcinoma. At a dose of 5 ,tg kg-' body weight thrice weekly, EB 1089 inhibited progression of established tumours in the absence of hypercalcaemia; animals did not lose weight and remained healthy. At the present time, the mechanisms by which EB 1089 may exert inhibitory effects on the growth of these pancreatic carcinoma cells is not clear. In MCF-7 breast cancer cells, the vitamin D analogue binds to VDR and strongly inhibits the proliferation of these cells with a potency 50-100 times that of 1,25(OH)2D3 (Colston et al, 1992b; Mathiasen et al, 1993) . It has also been demonstrated that EB 1089 increases expression of p53 protein in MCF-7 cells (James et al, 1995) , which acts as a cell cycle checkpoint regulator (Kuerbitz et al, 1992) . However, our preliminary findings presented here indicate that the effects of EB 1089 on GER cell growth are independent of changes in p53 expression.
Inhibitory effects of retinoids on the growth of human pancreatic cancer cells in vitro and in vivo have recently been reported (Bold et al, 1996) and EB 1089 has been demonstrated to enhance the growth-inhibitory effects of all-trans retinoic acid in certain pancreatic carcinoma cell lines (Zugmaier et al, 1996) . Our studies have additionally demonstrated that EB 1089 and 9-cis retinoic acid act separately to inhibit the growth of GER cells. We have already demonstrated that these compounds act in a co-operative manner to enhance induction of apoptosis in MCF-7 breast cancer cells (James et al, 1995) ; these observations, together with our present findings with pancreatic carcinoma cells, may have therapeutic implications. It is also important to note that neither of the two pancreatic carcinoma cell lines studied possessed oestrogen receptors. The absence of these receptors in some tumours may well account for the limited success of tamoxifen therapy in pancreatic carcinoma.
